Literature DB >> 16310930

Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.

Udo Jonas, Raymond R Rackley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16310930     DOI： 10.1016/j.eururo.2005.09.013

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  3 in total

1.  [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].

Authors:  M Goepel
Journal:  Urologe A       Date:  2006-07       Impact factor: 0.639

2.  [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].

Authors:  C Chapple
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

3.  A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with Solifenacin Plus Desmopressin, Tolterodine Plus Desmopressin, and Desmopressin alone: a randomized controlled clinical trial.

Authors:  Parvin Mousavi Ghanavati; Dinyar Khazaeli; Mohammadreza Amjadzadeh
Journal:  Int Braz J Urol       Date:  2021 Jan-Feb       Impact factor: 1.541
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.